Free Access
Med Sci (Paris)
Volume 38, Number 11, Novembre 2022
Page(s) 905 - 912
Section M/S Revues
Published online 30 November 2022
  1. Standards de soins. World Professional Association for Transgender Health. [Google Scholar]
  2. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017 ; 102 : 3869–3903. [CrossRef] [PubMed] [Google Scholar]
  3. Scheres LJJ, Selier NLD, Nota NM, et al. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost 2021; 19 : 1029–37. [CrossRef] [PubMed] [Google Scholar]
  4. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011 ; 164 : 635–642. [CrossRef] [PubMed] [Google Scholar]
  5. LaVasseur C, Neukam S, Kartika T, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost 2022; 6 : e12763. [CrossRef] [PubMed] [Google Scholar]
  6. Turino Miranda K, Kalenga CZ, Saad N, et al. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis. Am J Physiol Heart Circ Physiol 2022 Sep 2. doi: 10.1152/ajpheart.00299.2022. [PubMed] [Google Scholar]
  7. Iwamoto SJ, Defreyne J, Rothman MS, et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019 ; 10 : 2042018819871166. [CrossRef] [Google Scholar]
  8. Glintborg D, T’Sjoen G, Ravn P, Andersen MS. Management of endocrine disease: Optimal feminizing hormone treatment in transgender people. Eur J Endocrinol 2021; 185 : R49–R63. [CrossRef] [PubMed] [Google Scholar]
  9. [Google Scholar]
  10. Burinkul S, Panyakhamlerd K, Suwan A, et al. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. J Sex Med 2021; 18 : 1299–307. [CrossRef] [Google Scholar]
  11. Irwig MS. Is there a role for 5’-reductase inhibitors in transgender individuals? Andrology 2021; 9 : 1729–31. [CrossRef] [PubMed] [Google Scholar]
  12. Patel KT, Adeel S, Miragaya JR, Tangpricha V. Progestogen Use in Gender Affirming Hormone Therapy: A Systematic Review. Endocr Pract 2022 : S1530–891X(22)00600–0. [Google Scholar]
  13. Iwamoto SJ, T’Sjoen G, Safer JD, et al. Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen”. J Clin Endocrinol Metab 2019 ; 104 : 3127–3128. [CrossRef] [PubMed] [Google Scholar]
  14. Nolan BJ, Frydman AS, Leemaqz SY, et al. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocr Connect 2022; 11 : e220170. [CrossRef] [PubMed] [Google Scholar]
  15. de Blok CJM, Dijkman BAM, Wiepjes CM, et al. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. J Clin Endocrinol Metab 2021; 106 : e782–90. [CrossRef] [PubMed] [Google Scholar]
  16. Klaver M, de Blok CJM, Wiepjes CM, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol 2018 ; 178 : 163–171. [CrossRef] [PubMed] [Google Scholar]
  17. Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 2013 ; 54 : 92–97. [CrossRef] [PubMed] [Google Scholar]
  18. Verroken C, Collet S, Lapauw B, T’Sjoen G. Osteoporosis and Bone Health in Transgender Individuals. Calcif Tissue Int 2022; 110 : 615–23. [CrossRef] [PubMed] [Google Scholar]
  19. Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann Intern Med 2018 ; 169 : 205–213. [CrossRef] [PubMed] [Google Scholar]
  20. Streed CG, Jr, Harfouch O, Marvel F, et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med 2017 ; 167 : 256–267. [CrossRef] [PubMed] [Google Scholar]
  21. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2017 ; 102 : 3914–3923. [CrossRef] [PubMed] [Google Scholar]
  22. Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation 2019 ; 139 : 1461–1462. [CrossRef] [PubMed] [Google Scholar]
  23. Totaro M, Palazzi S, Castellini C, et al. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study. Front Endocrinol (Lausanne) 2021; 12 : 741866. [CrossRef] [PubMed] [Google Scholar]
  24. Cocchetti C, Castellini G, Iacuaniello D, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J Sex Med 2021; 18 : 821–9. [CrossRef] [PubMed] [Google Scholar]
  25. van Velzen DM, Adorni MP, Zimetti F, et al. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis 2021; 323 : 44–53. [CrossRef] [PubMed] [Google Scholar]
  26. Islam N, Nash R, Zhang Q, et al. Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort. J Clin Endocrinol Metab 2022; 107 : e1549–57. [CrossRef] [PubMed] [Google Scholar]
  27. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365 : l1652. [CrossRef] [PubMed] [Google Scholar]
  28. Baraban E, Ding CC, White M, et al. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy. Am J Surg Pathol 2022 Aug 26. doi: 10.1097/PAS.0000000000001964. [PubMed] [Google Scholar]
  29. Cocchetti C, Romani A, Collet S, et al. The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives. J Clin Med 2022; 11 : 1784. [CrossRef] [PubMed] [Google Scholar]
  30. Taub RL, Ellis SA, Neal-Perry G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020; 223 : 229.e1-8. [CrossRef] [PubMed] [Google Scholar]
  31. Mancini I, Alvisi S, Gava G, et al. Contraception across transgender. Int J Impot Res 2020; 33 : 710–9. [Google Scholar]
  32. Baker KE, Wilson LM, Sharma R, et al. Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review. J Endocr Soc 2021; 5 : bvab011. [CrossRef] [PubMed] [Google Scholar]
  33. Bultynck C, Pas C, Defreyne J, et al. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope 2017 ; 127 : 2796–2804. [CrossRef] [PubMed] [Google Scholar]
  34. Irwig MS, Childs K, Hancock ABEffects of testosterone on the transgender male voice. Andrology 2017 ; 5 : 107–112. [CrossRef] [PubMed] [Google Scholar]
  35. Scharff M, Wiepjes CM, Klaver M, et al. Change in grip strength in trans people and its association with lean body mass and bone density. Endocr Connect 2019 ; 8 : 1020–1028. [CrossRef] [PubMed] [Google Scholar]
  36. Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study. Maturitas 2018 ; 107 : 92–96. [CrossRef] [PubMed] [Google Scholar]
  37. Tebbens M, Nota NM, Liberton NPTJ, et al. Gender-Affirming Hormone Treatment Induces Facial Feminization in Transwomen and Masculinization in Transmen: Quantification by 3D Scanning and Patient-Reported Outcome Measures. J Sex Med 2019 ; 16 : 746–754. [CrossRef] [PubMed] [Google Scholar]
  38. Wiepjes CM, den Heijer M, T’Sjoen GGBone health in adult trans persons: an update of the literature. Curr Opin Endocrinol Diabetes Obes 2019 ; 26 : 296–300. [CrossRef] [PubMed] [Google Scholar]
  39. Wiepjes CM, Vlot MC, Klaver M, et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J Bone Miner Res 2017 ; 32 : 1252–1260. [CrossRef] [PubMed] [Google Scholar]
  40. Pirtea P, Ayoubi JM, Desmedt S, T’Sjoen G. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Fertil Steril 2021; 116 : 936–42. [CrossRef] [PubMed] [Google Scholar]
  41. Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. J Clin Endocrinol Metab 2021; 106 : 1710–7. [CrossRef] [PubMed] [Google Scholar]
  42. Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology 2018 ; 6 : 446–454. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.